Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Viral Genetics, Inc (VRAL: Pink Sheets) could be a multiple bagger over the next 6-18 months

Chart looks great and on a short term technical could have a big run!
 
We want to give our followers the heads up on Viral Genetics, Inc (VRAL: Pink Sheets), a Company we will be profiling (detailed profile report to follow later this week.):
 
Viral Genetics, Inc. is a biotechnology company that discovers and develops immune-based therapies for HIV and AIDS using its thymus nuclear protein compound (NYSE:TNP) and more recently experimentally and computationally derived targeted peptides. The company entered into, and recently expanded, an Exclusive License Agreement with the University of Colorado on technology developed by M. Karen Newell, PhD that appears to explain TNP and provide a means to optimize therapies based on the targeted peptides for future clinical trials. The licensed technology may have other potential applications for other infectious, autoimmune, and immunological deficiency diseases that the company intends to study in the future. Viral Genetics believes that its investigational HIV/AIDS drugs based on TNP, called VGV-1, and on its targeted peptides, called VGV-2, represent unique approaches to treating HIV due to the apparently novel mechanism, low toxicity profile, simple dosing regimen, and short-course of treatment. These technologies focus on boosting the immune system to allow the body to fight HIV more efficiently. VGV-1 had been studied in five human clinical trials for the treatment of HIV/AIDS. Work is progressing to initiate an IND application for VGV-2 with the FDA.
 
More to come in the next few days…..
 
21st Century Investor Relations provides investor relations 2.0 services to publicly traded companies looking to increase their investor audience over time through unique Internet marketing programs.

Investor Relations 2.0 is the use of second generation Internet - Web 2.0 - based services - such as social networking, platforms and tools to conduct investor relations. The central theme of IR 2.0 is getting found on the Internet by investors through blogging, social media, SEO, and lead conversion.
 
We have been engaged by a third party and have signed a 6 month contract to create Web 2.0 content and to help increase visibility, and online following through our proprietary Internet marketing methods.
 
Take a look at VRAL and do your homework as we believe this is a great place to get in based on a technical basis and before our Internet marketing campaign commences!!
21st Century Investor Relations, Inc is not registered as a securities broker-dealer or an investment advisor either with the SEC or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.http://www.21webir.com makes no recommendation that the purchase of securities of companies profiled on this web site or in this email are suitable or advisable for any person or that an investment in such securities will be profitable. For our disclosure and disclaimer details visit:http://21webir.com/stocks-and-sectors/disclaimer-for-viral-genetics-vral-pink-sheets/for-viral-genetics-vral-pink-sheets/